Estimates Revisions Denali Therapeutics Inc. Sao Paulo
Stocks
D2NL34
BRD2NLBDR008
Biotechnology & Medical Research
|
Market Closed -
Sao Paulo
14:04:39 2026-07-13 EDT
|
5-day change | 1st Jan Change | ||
| 27.06 BRL | -1.31% |
|
-.--% | +25.57% |
| 08-25 | B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating | MT |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- DNLI Stock
- D2NL34 Stock
- Consensus Denali Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
